Finger-Prick Autologous Blood in the Treatment of Persistent Corneal Epithelial Defects
Finger-Prick Autologous Blood in the Treatment of Persistent Corneal Epithelial Defects
复制标题
DOI：
10.1097/ico.0000000000002230
复制
发表时间：
2020-05-01
期刊：
影响因子：
2.8
通讯作者：
Sharma, Anant
中科院分区：
文献类型：
--
作者：
Balal, Shafi;Nitiahpapand, Rynda;Sharma, Anant
目的：自体血液衍生性滴眼液在永久性上皮缺陷(PED)的治疗中有一定作用，但其使用可能受到成本和可获得性的限制。指刺自体血液(FAB)治疗使用从消毒的指尖获得的整个毛细血管血液，作为血液衍生眼药水治疗的替代形式。到目前为止，已有1份报告描述了FAB安全有效地用于干眼和儿科疾病。我们报告了10只眼(10名患者)应用FAB治疗儿科疾病的结果。方法：糖尿病神经营养性角膜病变3例，疱疹病毒性角膜炎3例，穿透性角膜移植1例，干燥性角结膜炎1例，放射治疗后1例，神经性溃疡1例，平均259+/-201天，在常规治疗的基础上加用FAB，每天4次，共28天。在开始使用FAB之前，所有患者都接受了常规治疗，但均未成功。所有患者均未接受过PED的外科治疗。结果：术后第28天，60%(n=6)的眼PED愈合。1只眼PED缩小一半。30%(n=3)的患者在研究结束时有不完整的随访数据。结论：FAB联合常规治疗可成功治疗难治性PEDS。未观察到FAB治疗的不良反应。
Purpose: Autologous hemoderivative eye drops have a role in the management of persistent epithelial defects (PEDs), but their use may be limited by cost and availability. Finger-prick autologous blood (FAB) treatment uses whole capillary blood, obtained from a sterilized fingertip, as an alternative form of hemoderivative eye drop therapy. To date, 1 report has described the safe and effective use of FAB for dry eye and PEDs. We report the results of 10 eyes (10 patients) treated with FAB for PEDs. Methods: Ten patients with PEDs in 1 eye for a mean of 259 +/- 201 days due to diabetic neurotrophic keratopathy (n = 3), herpetic keratitis (n = 3), postpenetrating keratoplasty (n = 1), keratoconjunctivitis sicca (n = 1), postradiotherapy (n = 1), and neuropathic ulcer (n = 1) were treated with FAB 4 times a day for 28 days in addition to conventional therapies. All patients had been unsuccessfully treated with conventional therapy before commencing on FAB. None of the patients had received any surgical treatment for PED. Results: At day 28, the PED had healed in 60% (n = 6) of the eyes. In 1 eye, the PED reduced in size by half. Thirty percent (n = 3) of patients had incomplete follow-up data at the end of the study. Conclusions: FAB in combination with conventional treatment may be successfully used in the management of refractory PEDs. No adverse effects arising from FAB treatment were observed.